Phentermine — Discount Pricing

Other medications in Diabetes & Metabolism

• Pioglitazone
• Repaglinide
• Saxagliptin
• Semaglutide
• Semaglutide (Obesity)
• Sitagliptin
• Tirzepatide
• Tolvaptan

What Phentermine is approved for (FDA label)

Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m 2 , or ≥ 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). Below is a chart of body mass index (BMI) based on various heights and weights. BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.

Source: Read the full FDA label on DailyMed. Label effective date: August 17, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Phentermine (FDA label)

Capsules containing 37.5 mg phentermine hydrochloride (equivalent to 30 mg phentermine base). Tablets with a functional score containing 37.5 mg phentermine hydrochloride (equivalent to 30 mg phentermine base). • Capsules containing 37.5 mg phentermine hydrochloride. () • Tablets with a functional score containing 37.5 mg phentermine hydrochloride. ()

Source: FDA prescribing information (DailyMed). Set ID: 129e781c-5366-4986-8e67-6b35fa4c3f39. SPL document ID: 479c0390-9f86-4e3a-b4bd-fc81d7d799f1. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Phentermine (FDA label)

The following adverse reactions are described, or described in greater detail, in other sections: • Primary pulmonary hypertension [ see Warnings and Precautions ( 5.2 ) ] • Valvular heart disease [ see Warnings and Precautions ( 5.3 ) ] • Effect on the ability to engage in potentially hazardous tasks [ see Warnings and Precautions ( 5.5 ) ] • Withdrawal effects following prolonged high dosage administration [ see Drug Abuse and Dependence ( 9.3 ) ] The following adverse reactions to phentermine have been identified: Cardiovascular Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure, ischemic events. Central Nervous System Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis.

Source: FDA prescribing information (DailyMed). Set ID: 129e781c-5366-4986-8e67-6b35fa4c3f39. SPL document ID: 479c0390-9f86-4e3a-b4bd-fc81d7d799f1. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Phentermine (FDA label)

• History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within 14 days following the administration of monoamine oxidase inhibitors ( 4 ) • Hyperthyroidism ( 4 ) • Glaucoma ( 4 ) • Agitated states ( 4 ) • History of drug abuse ( 4 ) • Pregnancy ( 4 , 8.1 ) • Nursing ( 4 , ) • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 129e781c-5366-4986-8e67-6b35fa4c3f39. SPL document ID: 479c0390-9f86-4e3a-b4bd-fc81d7d799f1. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Phentermine (FDA label)

• Coadministration with other drugs for weight loss is not recommended (safety and efficacy of combination not established). ( 5.1 ) • Rare cases of primary pulmonary hypertension have been reported. Phentermine should be discontinued in case of new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema. ( 5.2 ) • Rare cases of serious regurgitant cardiac valvular disease have been reported. ( 5.3 ) • Tolerance to the anorectic effect usually develops within a few weeks. If this occurs, Phentermine should be discontinued. The recommended dose should not be exceeded. ( 5.4 ) • Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle. ( 5.5 ) • Risk of abuse and dependence.

Source: FDA prescribing information (DailyMed). Set ID: 129e781c-5366-4986-8e67-6b35fa4c3f39. SPL document ID: 479c0390-9f86-4e3a-b4bd-fc81d7d799f1. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Phentermine (FDA label)

• Monoamine oxidase inhibitors: Risk of hypertensive crisis. ( 4 , 7.1 ) • Alcohol: Consider potential interaction ( 7.2 ) • Insulin and oral hypoglycemics: Requirements may be altered. ( 7.3 ) • Adrenergic neuron blocking drugs: Hypotensive effect may be decreased by phentermine. ( 7.4 ) 7.1 Monoamine Oxidase Inhibitors Use of phentermine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of hypertensive crisis. 7.2 Alcohol Concomitant use of alcohol with phentermine may result in an adverse drug reaction. 7.3 Insulin and Oral Hypoglycemic Medications Requirements may be altered [ see Warnings and Precautions ( 5.9 ) ]. 7.4 Adrenergic Neuron Blocking Drugs Phentermine may decrease the hypotensive effect of adrenergic neuron blocking drugs.

Source: FDA prescribing information (DailyMed). Set ID: 129e781c-5366-4986-8e67-6b35fa4c3f39. SPL document ID: 479c0390-9f86-4e3a-b4bd-fc81d7d799f1. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.